First Trust Advisors’s Immunocore IMCR Stock Holding History

First Trust Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-19,826	Closed	-$1.03M	–	2384
2023 Q3	$1.03M	Sell	19,826 -5,154	-21%	-$305K	﹤0.01%	1956
2023 Q2	$1.5M	Buy	+24,980	New	+$1.43M	﹤0.01%	1842
2023 Q1	–	Sell	-13,975	Closed	-$798K	–	2413
2022 Q4	$798K	Buy	+13,975	New	+$787K	﹤0.01%	2035

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

First Trust Advisors's IMCR Position: Q4 2023 in Review

First Trust Advisors sold out of Immunocore (IMCR) in Q4 2023, closing a stake of 19,826 shares — an estimated $1.03M sold.

First Trust Advisors first reported a position in IMCR in Q4 2022 and held it in 3 quarters. The position peaked at $1.5M in Q2 2023. 133 funds tracked by Wall St. Rank hold IMCR as of Q4 2023.

First Trust Advisors reported no remaining Immunocore position as of Q4 2023 after selling out during the quarter.
First Trust Advisors sold 19,826 Immunocore shares in Q4 2023, an estimated $1.03M.
First Trust Advisors first reported a position in Immunocore in Q4 2022 and held it in 3 quarters.
First Trust Advisors's Immunocore position peaked at $1.5M in Q2 2023.
133 funds tracked by Wall St. Rank held Immunocore as of Q4 2023.

Based on First Trust Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.